Q-omics provides the consensus-scored PSMD5 profile across patient tissues and cancer cell-line models. PSMD5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PSMD5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PSMD5 protein abundance shows 20,326 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where PSMD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMD5 survival associations across molecular data types. PSMD5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMD5 RNA expression–survival associations across cancer types. High PSMD5 expression shows unfavorable associations in ACC, LGG, UVM, HNSC and MESO, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PSMD5 RNA expression.
This table summarizes PSMD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMD5 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, STAD and BRCA. The HNSC box plot shows higher PSMD5 RNA expression in tumor versus normal tissue (log2 FC = +0.974, t-test p < 0.001).
This table shows molecular features associated with PSMD5 in patient tissues and cancer cell lines. In patient samples, PSMD5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
